133339-10-3

Upstream product

• 110-91-8 morpholine 
• 1523-21-3 4-nitrophenyl 3,5-dinitrobenzoate 
• 99-33-2 3,5-dinitrobenoyl chloride 
• 99-34-3 3,5-dinitrobenzoic acid 

Downstream Products

• 503164-67-8 3-(morpholinomethyl)-5-nitroaniline 
• 313233-13-5 (3,5-diaminophenyl)(morpholin-4-yl)methanone 

Relevant academic research and scientific papers

Evidence for a catalytic six-membered cyclic transition state in aminolysis of 4-nitrophenyl 3,5-dinitrobenzoate in acetonitrile: Comparative Br?nsted-type plot, entropy of activation, and deuterium kinetic isotope effects

A kinetic study for reactions of 4-nitrophenyl 3,5-dinitrobenzoate (1a) with a series of cyclic secondary amines in acetonitrile is reported. Plots of the pseudo-firstorder rate constant (kobsd) vs [amine] curve upward, while those of kobs

Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors

Glycogen synthase kinase-3 (GSK-3) plays an important regulatory role in various signaling pathways; such as PI3 K/AKT, which is closely related to the occurrence and development of tumors. At present, the most reported active GSK-3 inhibitors have the same structure: lactam ring or amide structure. To find out the GSK-3β small molecule inhibitor with novel, safe, efficient and more uncomplicated synthesis method, we analyzed in-depth reported crystal-binding patterns of GSK-3β small molecule inhibitor with GSK-3β protein, and designed and synthesized 17 non-reported 3,5-diamino-N-substituted benzamide compounds. Their structures were confirmed by 1H-NMR, 13C-NMR, and HR-MS. The preliminary screening of tumor cytotoxicity of compounds in vitro was detected by MTT, and their structure–activity relationships were illustrated. The results have shown that 3,5-diamino-N-[3-(trifluoromethyl)phenyl]benzamide (4d) exhibited significant tumor cytotoxicity against human colon cancer cells (HCT-116) with IC50 of 8.3 μm and showed commendable selectivity to GSK-3β. In addition, Compound 4d induced apoptosis to some extent and possessed modest PK properties.

2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof

The invention discloses 2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof. The structure of the 2-aminopyrimidine compounds is shown in the formula I, definitions of R1, R2, R3, R4, R5, X, Y, Z and W in the formula are shown in the specification and the claim. The compounds can effectively inhibit growths of a plurality of tumor cells, generate inhibition effects for EGFR and IGF1R protease, and is used for preparing antitumor drugs; the compounds can overcome drug resistance which is induced by prior medicaments Gefitinib and Erlotinib and the like, has selectivity for tumor, especially wild type non-small cell lung cancers, and has good pharmacokinetics property.